Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 2/3 1Phase 1 1

Status

Recruiting 3Enrolling by invitation 1

Sponsor Class

INDUSTRY 2OTHER_GOV 1OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Other solid neoplasm 67Other hematologic neoplasm 47Thoracic 31Gastrointestinal 27Breast 26Myeloid 20Lymphoid 20Gynecologic 15Genitourinary 9Plasma cell 7Sarcoma 5Head & Neck 5CNS 5NET 4Endocrine 4Dermatologic 4Classical hematology 4Tumor-Agnostic 3

Conditions

Neuroendocrine Tumors 3Tuberous Sclerosis 1Neoplasms 1Gastroenteropancreatic Neuroendocrine Tumors 1Carcinoma, Renal Cell 1Carcinoma, Hepatocellular 1Adenoma, Islet Cell 1

Interventions

lutetium Lu 177 dotatate 29Magnetic Resonance Spectroscopy 15Everolimus 10pembrolizumab 9Specimen Handling 9cabozantinib 7Nivolumab 7Lutetium-177 6surufatinib 5lenvatinib 5Octreotide 5Capecitabine 5177Lu-octreotide, DOTA(0)-Tyr(3)- 5olaparib 4lanreotide 4gallium Ga 68 dotatate 4amino-acid, glucose, and electrolyte solution 4X-Rays 4Lutetium 4Ipilimumab 4Injections 4Fluorodeoxyglucose F18 4copper dotatate CU-64 3atezolizumab 3Temozolomide 3Ga(III)-DOTATOC 3Cyclophosphamide 3Carboplatin 3pasireotide 2fludarabine phosphate 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Injections × NET × 1 year × Clear all
NCT07165886 2026-04-24

Sirolimus for Injection (Albumin Bound) Combined With Octreotide Long-acting Injection in Patients With Metastatic Gastroenteropancreatic Neuroendocrine Tumors

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Phase 2/3 Recruiting
298 enrolled
EndocrineGastrointestinalNET

Gastroenteropancreatic Neuroendocrine Tumors

NCT07369505 2026-01-27

Sapu003 in Advanced mTOR-sensitive Solid Tumors

SAPU NANO (US) LLC

Phase 1 Recruiting
27 enrolled
EndocrineGastrointestinalGenitourinaryNET

Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Tuberous Sclerosis, Neuroendocrine Tumors

NCT07121478 2025-10-01

Patients With High-grade Pancreatic Neuroendocrine Tumors

National Cancer Center, Korea

Phase 2 Enrolling by invitation
46 enrolled
EndocrineNET

Adenoma, Islet Cell, Neuroendocrine Tumors

NCT04837885 2025-07-23

LUTARTERIAL

University Hospital, Bordeaux

Phase 2 Recruiting
23 enrolled
EndocrineNET

Neoplasms, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡